SCScarlett Se Yun Cheon

Scarlett Se Yun Cheon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Scarlett Se Yun Cheon has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Aisha Mohamed

    Medicine/General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

    2 shared publications
  • Dahlene N. Fusco

    Medicine/General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

    2 shared publications
  • Gonzague Jourdain

    French National Research Institute for Sustainable Development (IRD), Marseille, France

    2 shared publications
  • Raymond T. Chung

    Medicine/General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

    2 shared publications
  • Shadmehr Demehri

    Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

    2 shared publications
  • Amir H. Ameri

    Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA

    1 shared publication

Latest Publications

  • IL-33/Regulatory T-Cell Axis Suppresses Skin Fibrosis

    by Se Yun Cheon, Jong Ho Park, Amir H. Ameri, Richard T. Lee, Rosalynn M. Nazarian, Shadmehr Demehri


  • Open Access

    Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells

    by Erik B. Schiferle, Se Yun Cheon, Seokjin Ham, Heehwa G. Son, Jonathan L. Messerschmidt, Donald P. Lawrence, Justine V. Cohen, Keith T. Flaherty, James J. Moon, Christine G. Lian, et al.

    Melanoma and melanocytic nevi harbor shared lineage-specific antigens and oncogenic mutations. Yet, the relationship between the immune system and melanocytic nevi is unclear. Using a patient-derived xenograft (PDX) model, we found that 81.8% of the transplanted nevi underwent spontaneous regression, while peripheral skin remained intact. Nevus-resident CD4+ T helper 1 cells, which exhibited a massive clonal expansion to melanocyte-specific antigens, were responsible for nevus rejection. Boosting regulatory T cell suppressive function with low-dose exogenous human interleukin-2 injection or treatment with a human leukocyte antigen (HLA) class II–blocking antibody prevented nevus rejection. Notably, mice with rejected nevus PDXs were protected from melanoma tumor growth. We detected a parallel CD4+ T cell–dominant immunity in clinically regressing melanocytic nevi. These findings reveal a mechanistic explanation for spontaneous nevus regression in humans and posit the activation of nevus-resident CD4+ effector T cells as a novel strategy for melanoma immunoprevention and treatment.


  • Open Access

    Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy

    by Dahlene N. Fusco, Lilia Ganova-Raeva, Yury Khudyakov, Lili Punkova, Aisha Mohamed, Scarlett Se Yun Cheon, Prapti Koirala, Karin L. Andersson, Gonzague Jourdain, Camille Sureau, et al.

    A 76-year-old Cambodian man co-infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) 6c-1 presented for care. HBV DNA was intermittently detectable despite anti-HBs levels being above the protective threshold. During treatment for HCV, HBV DNA levels increased. Sequencing revealed multiple mutations including vaccine escape mutation and mutations predicted to enhance fitness. This case represents exacerbation of an HBV vaccine escape mutant during a direct-acting antiviral therapy.


  • Open Access

    Hepatitis B virus outreach to immigrant population in Greater Boston Area: Key to improving hepatitis B knowledge

    by Raissa Djoufack, Scarlett Se Yun Cheon, Aisha Mohamed, Fatou Faye, Korka Diouf, Richard Colvin, James Morrill, Ann-Marie Duffy-Keane, Ponni Perumalswami, Gonzague Jourdain, et al.

    Hepatitis B virus outreach to immigrant population in Greater Boston Area: Key to improving hepatitis B knowledge


  • Open Access

    HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus

    by Dahlene N. Fusco, Henry Pratt, Stephen Kandilas, Scarlett Se Yun Cheon, Wenyu Lin, D. Alex Cronkite, Megha Basavappa, Kate L. Jeffrey, Anthony Anselmo, Ruslan Sadreyev, et al.

    Flaviviral infections including dengue virus are an increasing clinical problem worldwide. Dengue infection triggers host production of the type 1 IFN, IFN alpha, one of the strongest and broadest acting antivirals known. However dengue virus subverts host IFN signaling at early steps of IFN signal transduction. This subversion allows unbridled viral replication which subsequently triggers ongoing production of IFN which, again, is subverted. Identification of downstream IFN antiviral effectors will provide targets which could be activated to restore broad acting antiviral activity, stopping the signal to produce endogenous IFN at toxic levels. To this end, we performed a targeted functional genomic screen for IFN antiviral effector genes (IEGs), identifying 56 IEGs required for antiviral effects of IFN against fully infectious dengue virus. Dengue IEGs were enriched for genes encoding nuclear receptor interacting proteins, including HELZ2, MAP2K4, SLC27A2, HSP90AA1 and HSP90AB1. We focused on HELZ2 (Helicase With Zinc Finger 2), an IFN stimulated gene and IEG which encodes a promiscuous nuclear factor coactivator that exists in two isoforms. The two unique HELZ2 isoforms are both IFN responsive, contain ISRE elements, and gene products increase in the nucleus upon IFN stimulation. Chromatin immunoprecipitation-sequencing revealed that the HELZ2 complex interacts with triglyceride-regulator LMF1. Mass spectrometry revealed that HELZ2 knockdown cells are depleted of triglyceride subsets. We thus sought to determine whether HELZ2 interacts with a nuclear receptor known to regulate immune response and lipid metabolism, AHR, and identified HELZ2:AHR interactions via co-immunoprecipitation, found that AHR is a dengue IEG, and that an AHR ligand, FICZ, exhibits anti-dengue activity. Primary bone marrow derived macrophages from HELZ2 knockout mice, compared to wild type controls, exhibit enhanced dengue infectivity. Overall, these findings reveal that IFN antiviral response is mediated by HELZ2 transcriptional upregulation, enrichment of HELZ2 protein levels in the nucleus, and activation of a transcriptional program that appears to modulate intracellular lipid state. IEGs identified in this study may serve as both 1) potential targets for host directed antiviral design, downstream of the common flaviviral subversion point, as well as 2) possible biomarkers, whose variation, natural or iatrogenic, could affect host response to viral infections.